Osimertinib Mesylate from China
Osimertinib mesylate is a third-generation EGFR TKI for lung cancer with T790M mutation. The indoline-quinazoline structure qualifies as aromatic modified heterocyclic drug under HTS 2933.99.75.00.
Duty Rate — China → United States
19%
Rate breakdown
9903.05.3112.5%Section 301 (forced labor) — additional 12.5% ad valorem on products of China
Import Tips
• Include polymorphic form designation (Form A) in import documentation
• Particle size distribution critical for bioavailability - include laser diffraction data
• Declare therapeutic class on entry summary to facilitate FDA review